publication venue for
- OC4. Number and sites of bone lesions and history of skeletal-related events (SREs): Do these parameters correspond with skeletal morbidity and mortality in patients with bone metastases (mets) from hormone-refractory prostate cancer (HRPC)? 2008
- P79. N-Telopeptide of type I collagen (NTX) levels and prognosis in patients with bone metastases from non-small cell lung cancer (NSCLC) receiving zoledronic acid (ZOL) or placebo 2008
- P81. Meta-analysis of effects of zoledronic acid (ZOL) on survival in patients with metastatic bone disease (MBD) and high bone turnover 2008
- The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma – A systematic review. 118:102584-102584. 2023
- Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada. 115:102526-102526. 2023
- Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: A systematic review. 87:102032-102032. 2020
- An evidence-based guideline on the application of molecular testing in the diagnosis, prediction of prognosis, and selection of therapy in non-GIST soft tissue sarcomas. 85:101987-101987. 2020
- Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis. 80:101895-101895. 2019
- Network meta-analysis of therapies for previously untreated advanced BRAF-mutated melanoma. 74:43-48. 2019
- Molecular analyses in the diagnosis and prediction of prognosis in non-GIST soft tissue sarcomas: A systematic review and meta-analysis. 66:74-81. 2018
- Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC. 65:65-77. 2018
- Staging and surgical approaches in gastric cancer: A systematic review. 63:104-115. 2018
- Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck. 54:43-57. 2017
- Approach to evaluation of fever in ambulatory cancer patients receiving chemotherapy: A systematic review. 51:35-45. 2016
- Bone markers and their prognostic value in metastatic bone disease: Clinical evidence and future directions. 34:629-639. 2008
- A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. 34:442-452. 2008
- Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: A systematic review. 34:157-174. 2008
- Common cancers in adolescents. 33:597-602. 2007
- Rituximab in lymphoma: A systematic review and consensus practice guideline from Cancer Care Ontario. 33:161-176. 2007
- Adjuvant chemotherapy with uracil-tegafur prolongs overall survival in people with primary adenocarcinoma of the lung. 30:661-664. 2004
- Adjuvant chemotherapy with uracil–tegafur prolongs overall survival in people with primary adenocarcinoma of the lung☆☆☆☆☆☆Abstracted from: Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil–tegafur for adenocarcinoma of the lung. N Engl J Med 2004;350:1713–21.. 30:661-664. 2004
- Gefitinib does not improve survival when combined with gemcitabine and cisplatin in people with advanced non-small-cell lung cancer☆☆☆☆☆☆Abstracted from: Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004;22:777–784.. 30:651-653. 2004
- Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer☆☆☆☆Abstracted from: Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol 2004;22:785–94.. 30:655-659. 2004
- Can we optimise treatment of thrombosis?. 29:19-22. 2003
- Introduction. 29:1-1. 2003
- Introduction: building on a heritage in thrombosis – perspectives in cancer care. 28:131-131. 2002
- Managing thromboembolic disease in the cancer patient: efficacy and safety of antithrombotic treatment options in patients with cancer. 28:145-149. 2002
- What is the role for antithrombotics in cancer care?. 28:157-159. 2002
- Integration of Chinese medicine into supportive cancer care:A modern role for an ancient tradition. 27:235-246. 2001
- Randomized trial of group psychosocial support in metastatic breast cancer: the BEST study. 22:91-96. 1996
- Nitric oxide and anti-cancer therapy. 21:159-181. 1995
- Tumour blood flow: measurement and manipulation for therapeutic gain. 19:299-349. 1993
- The current role of anti-emetic drugs in oncology: a recent revolution in patient symptom control. 18:95-135. 1991
- Non-chemotherapeutic agents that potentiate chemotherapy efficacy. 16:1-40. 1989